ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation in completely resected (stage I-III) non small cell lung cancer (NSCLC) patients (pts)

被引：6
|
作者：
Rosell, R
de Lena, M
Carpagnano, F
Ramlau, R
Gonzalez-Larriba, J
Grodzki, T
Le Groumellec, A
Aubert, D
Gasmi, J
Douillard, J
机构：
[1] Catalan Inst Oncol, Badalona, Spain
[2] IRCCS, Bari, Italy
[3] Osped San Paolo, Bari, Italy
[4] Lung Hosp, Poznan, Poland
[5] Hosp Clin San Carlos, Madrid, Spain
[6] Reg Hosp Lung Dis, Szczecin, Poland
[7] CH Chubert, Vannes, France
[8] Ctr Rech Pierre Fabre, Castres, France
[9] Ctr Rene Gauducheau, F-44035 Nantes, France
来源：
LUNG CANCER | 2005年 / 49卷
关键词：
D O I：
10.1016/S0169-5002(05)80129-1
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：S3 / S4
页数：2
相关论文
共 50 条
  • [1] ANITA: Phase III adjuvant vinorelbine (N) and cisplatin (P) versus observation (OBS) in completely resected (stage I-III) non-small-cell lung cancer (NSCLC) patients (pts): Final results after 70-month median follow-up. On behalf of the Adjuvant Navelbine International Trialist Association.
    Douillard, JY
    Rosell, R
    Delena, M
    Legroumellec, A
    Torres, A
    Carpagnano, F
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 624S - 624S
  • [2] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
    Makoto Sonobe
    Ken-ichi Okubo
    Satoshi Teramukai
    Kazuhiro Yanagihara
    Masaaki Sato
    Toshihiko Sato
    Fengshi Chen
    Kiyoshi Sato
    Takuji Fujinaga
    Tsuyoshi Shoji
    Mitsugu Omasa
    Hiroaki Sakai
    Ryo Miyahara
    Toru Bando
    Hiroshi Date
    [J]. Cancer Chemotherapy and Pharmacology, 2014, 74 : 1199 - 1206
  • [3] Phase II study of adjuvant vinorelbine and cisplatin in Japanese patients with completely resected stage II and III non-small cell lung cancer
    Sonobe, Makoto
    Okubo, Ken-ichi
    Teramukai, Satoshi
    Yanagihara, Kazuhiro
    Sato, Masaaki
    Sato, Toshihiko
    Chen, Fengshi
    Sato, Kiyoshi
    Fujinaga, Takuji
    Shoji, Tsuyoshi
    Omasa, Mitsugu
    Sakai, Hiroaki
    Miyahara, Ryo
    Bando, Toru
    Date, Hiroshi
    [J]. CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2014, 74 (06) : 1199 - 1206
  • [4] Improved disease-free durvival and dverall durvival by navelbine (N) and cisplatin (P) as adjuvant chemotherapy in completely resected (Stage I-III) non small cell lung cancer (NSCLC): ANITA trial. on behalf of adjuvant navelbine international trial association
    De Lena, M.
    Carpagnano, F.
    Monnier, A.
    Gonzales-Larriba, J.
    Astudillo, J.
    Bryl, M.
    Grodzki, T.
    Dahabreh, J.
    Rodrigues-Pereira, J.
    Douillard, J.
    [J]. EJC SUPPLEMENTS, 2005, 3 (02): : 325 - 325
  • [5] Impact of histology on survival in resected patients with Non Small Cell Lung Cancer (NSCLC): Subgroup analysis of the adjuvant vinorelbine (NVB) cisplatin (CDDP) versus observation ANITA trial
    Douillard, J. Y.
    [J]. EJC SUPPLEMENTS, 2009, 7 (02): : 508 - 508
  • [6] A phase III adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients (pts) with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC): An interim preliminary result.
    Jie, H.
    Xiangru, Z.
    Han, B.
    Liu, Y.
    Wang, Q.
    Xu, S.
    Sheng, Y.
    Li, Q.
    Wu, S.
    Chen, C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [7] Updated survival analysis of JBR.10: A randomized phase III trial of vinorelbine/cisplatin versus observation in completely resected stage IB and II non-small cell lung cancer (NSCLC)
    Vincent, M. D.
    Butts, C.
    Seymour, L.
    Ding, K.
    Graham, B.
    Twumasi-Ankrah, P.
    Gandara, D.
    Schiller, J.
    Green, M.
    Shepherd, F.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [8] AN UPDATE OF THE PHASE III STUDY OF ADJUVANT VINORELBINE PLUS CISPLATIN (NP) VERSUS NP PLUS ENDOSTAR (NPE) IN PATIENTS WITH COMPLETELY RESECTED STAGE IB-IIIA NON-SMALL CELL LUNG CANCER (NSCLC)
    He, Jie
    Zhang, Xiangru
    Li, Junling
    Han, Baohui
    Liu, Yongyu
    Wu, Shixiu
    Kuang, Y.
    Shen, Yi
    Chen, Chun
    Wang, Qun
    Li, Qiang
    Ma, Haitao
    Xu, Shidong
    Xu, Shaofa
    Wang, P.
    Mao, Weimin
    Pang, Z.
    Hou, S.
    Yang, Y.
    [J]. JOURNAL OF THORACIC ONCOLOGY, 2011, 6 (06) : S1318 - S1319
  • [9] Update of a phase III trial of adjuvant vinorelbine plus cisplatin (NP) versus NP plus endostar (NPE) in patients with completely resected stage IB-IIIA non-small cell lung cancer (NSCLC)
    Jie, He
    Han, Baohui
    Liu, Yongyu
    Wu, Shi Xiu
    Kuang, Yukang
    Shen, Yi
    Chen, Chun
    Wang, Qun
    Li, Qiang
    Ma Haitao
    Xu, Shaofa
    Xu, Shidong
    Wang, Ping
    Mao, Weimin
    Pang, Zuoliang
    Hou, Shengcai
    Yang, Yue
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2012, 30 (15)
  • [10] CANOPY-A: Phase III study of canakinumab (CAN) as adjuvant therapy in patients (pts) with completely resected non-small cell lung cancer (NSCLC)
    Garon, E. B.
    Lu, S.
    Goto, Y.
    De Marchi, P. R.
    Paz-Ares, L.
    Spigel, D. R.
    Thomas, M.
    Yang, J. C-H.
    Ardizzoni, A.
    Barlesi, F.
    Khanna, S.
    Bossen, C.
    Carbini, M.
    Yovine, A.
    Cho, B. C.
    [J]. ANNALS OF ONCOLOGY, 2022, 33 (07) : S1414 - S1415
12345